21 Crouzon syndrome is a congenital disorder characterized by craniosynostosis, the premature 22 fusion of cranial bones. Craniosynostosis leads to high intracranial pressure and abnormal skull 23 and facial shapes that are relieved by surgery. Crouzon syndrome is caused by activating 24 mutations in fibroblast growth factor receptor 2 (FGFR2). The goal of this study was to 25 determine if delivery of recombinant tissue nonspecific alkaline phosphatase (TNAP) could 26 prevent or diminish the severity of craniosynostosis in post-natal craniosynostosis onset BALB/c 27 and/or peri-natal craniosynostosis onset C57BL/6 FGFR2 C342Y/+ mouse models of Crouzon 28 syndrome. Mice were injected with a lentivirus encoding a mineral targeted form of TNAP 29 immediately after birth. Cranial bone fusion as well as cranial bone volume, mineral content 30 and density were assessed by micro computed tomography. Craniofacial shape was measured 31 with calipers using previously established landmarks and measurements. Alkaline phosphatase 32 activity levels were measured in serum. Results show that postnatal delivery of TNAP increases 33 serum levels of alkaline phosphatase activity and improves bone volume, density and mineral 34 content, but does not alleviate craniosynostosis, craniofacial shape or cranial base 35 abnormalities in FGFR2 C342Y/+ Crouzon mice. These results indicate that post-natal recombinant 36 TNAP enzyme therapy is therapeutic for bone mineralization but not efficacious for relief of 37 FGFR-associated craniosynostosis and associated craniofacial shape defects.
. BALB/c Crouzon mice injected with the lentivirus 157 increased serum AP levels by 1.2 U/mL when compared to control Crouzon mice (p<.0001) 158 when measured at four weeks old. C57BL/6 Crouzon mice injected with the TNAP expression 159 lentivirus increased serum AP levels by 1.8 U/mL when compared to control Crouzon mice 160 (p<.0001) when measured at three weeks old. No significant difference in serum AP levels were 161 seen between untreated Crouzon and wild type mice on the BALB/c or C57BL/6 backgrounds.
162 As expected, injection with the lentivirus did not alter serum inorganic phosphate (P i ) levels.
163
Initial statistical comparison of groups by ANOVA showed that Crouzon mice weigh less and 164 are shorter in body length than their wild type littermates, regardless of genetic background 165 (Table 1) . Linear regression performed to account for serum AP level variability in the lentivirus 166 injected mice showed that, on the BALB/c background, serum AP levels did not alter weight in 167 wild type mice but did decrease weight in Crouzon mice by 0.9 g per U/ml which accounted for 168 37% of the weight variability in in these mice (p<.03). On the C57BL/6 background, linear 169 regression showed no impact of serum AP level on weight, regardless of genotype. Serum AP 170 levels did not alter body length, regardless of genetic background or genotype.
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